Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000907 · ClinicalTrials.gov registry record

A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients

A clinical trial of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
50
Enrollment target
20
Study locations

NCT00000907 is a study of HIV Infections and Mycobacterium Avium-Intracellulare Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 50 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000907, a study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
50 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the effects of stopping preventive therapy for DMAC in HIV-positive patients who (1) have been treated for DMAC for at least 12 months and are now free of any signs of DMAC for at least 16 weeks, and (2) have improved immune systems (CD4 cell counts greater than or equal to 100 cells/mm3) due to anti-HIV drug therapy. DMAC is a serious and sometimes life-threatening infection that usually affects only HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) less than 50 cells/mm3. It is recommended that people who are likely to get DMAC be placed on preventive medications which help reduce the risk of infection. New anti-HIV combination drug therapies can increase CD4 cell counts and can reduce the level of HIV in the blood. When CD4 counts are increased, risk of DMAC infection is less. This study examines whether it is possible to stop preventive therapy for DMAC when CD4 counts are high without placing individuals at risk for getting DMAC again.

Conditions Studied

HIV Infections Mycobacterium Avium-Intracellulare Infection

Study Locations (20)

California

  • Univ of Southern California / LA County USC Med Ctr - Los Angeles
  • Willow Clinic - Menlo Park
  • Univ of California / San Diego Treatment Ctr - San Diego
  • San Francisco AIDS Clinic / San Francisco Gen Hosp - San Francisco
  • San Francisco Gen Hosp - San Francisco
  • Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium - San Jose
  • San Mateo AIDS Program / Stanford Univ - Stanford
  • Stanford Univ Med Ctr - Stanford

New York

  • SUNY / Erie County Med Ctr at Buffalo - Buffalo
  • Beth Israel Med Ctr - New York
  • Bellevue Hosp / New York Univ Med Ctr - New York
  • Mount Sinai Med Ctr - New York

Indiana

  • Indiana Univ Hosp - Indianapolis
  • Division of Inf Diseases/ Indiana Univ Hosp - Indianapolis

Colorado

  • Univ of Colorado Health Sciences Ctr - Denver

Florida

  • Univ of Miami School of Medicine - Miami

Georgia

  • Emory Univ - Atlanta

Hawaii

  • Univ of Hawaii - Honolulu

Illinois

  • Rush Presbyterian - Saint Luke's Med Ctr - Chicago

Trial Details

FieldValue
Enrollment Target 50 participants

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00000907

The ClinicalTrials.gov registry entry for NCT00000907 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.

NCT00000907 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, New York, Indiana.

Frequently Asked Questions

What is clinical trial NCT00000907 about?

NCT00000907 is a clinical study titled "A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients". The purpose of this study is to evaluate the effects of stopping preventive therapy for DMAC in HIV-positive patients who (1) have been treated for DMAC for at least 12 months and are now free of any signs of DMAC for at least 16 weeks, and (2) have improved immune systems (CD4 cell counts greater t...

What is the current status of trial NCT00000907?

This trial is currently completed. The enrollment target is 50 participants.

What conditions does trial NCT00000907 study?

This clinical trial studies the following conditions: HIV Infections, Mycobacterium Avium-Intracellulare Infection.

Who is sponsoring clinical trial NCT00000907?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000907 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Mycobacterium Avium-Intracellulare Infection

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.